API CAS 322-35-0 Benserazide HCl Pharmaceutical Raw Material Benserazide Hydrochloride Powder Benserazide

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Benserazide
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Benserazide
• Name: Benserazide Powder
• Appearance: White to off White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Antiparkinsonian
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 322-35-0
• Mf: C10h15n3o5
• MW: 257.2432
• Density: 1.541
• Boiling Point: 574.2 C at 760 Mmhg
• Refractive Index: 1.678
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 3 Ton/Month

Product Description

API CAS 322-35-0 Benserazide Hcl Pharmaceutical Raw Material Benserazide Hydrochloride Powder Benserazide

 

Product Description

Product Details

Product Name	Benserazide
CAS No.	322-35-0
MF	C10H15N3O5
MW	257.2432
Appearance and shape	White to off white crystalline powder

Benserazide hydrochloride is a peripheral decarboxylase inhibitor, combined with levodopa to make a compound preparation dopasizide. Levodopa is an effective drug for the treatment of Parkinson's disease. Its pharmacological effect is realized by converting it into dopamine by decarboxylase in the brain. Dopamine in the brain can improve Parkinson's disease. However, most of levodopa is converted into dopamine by the action of aromatic amino acid decarboxylase (AADC) in the external Chemicalbook, and only a small amount can enter the brain. Benserazide hydrochloride is used as an AADC inhibitor in combination with levodopa to inhibit levodopa It is converted into dopamine in the periphery, thereby increasing the amount of levodopa entering the brain, effectively improving the symptoms of Parkinson's disease.

Application & Function

Benserazide is an inhibitor of aromatic L-amino acid decarboxylase (AADC), an enzyme that has dopamine decarboxylase activity. It is also unable to cross the blood-brain barrier. As a result, benserazide blocks the conversion of L-DOPA to dopamine by AADC in the peripheral circulatory system. Benserazide is often combined with L-DOPA in patients with Parkinson's disease.

Specification